MorphoSys (MOR) Competitors $18.96 0.00 (0.00%) As of 05/22/2026 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock MOR vs. ARWR, ELAN, RDY, ABVX, and PRAXShould you buy MorphoSys stock or one of its competitors? MarketBeat compares MorphoSys with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MorphoSys include Arrowhead Pharmaceuticals (ARWR), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Abivax (ABVX), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. MOR vs. ARWRMOR vs. ELANMOR vs. RDYMOR vs. ABVXMOR vs. PRAXHow does MorphoSys compare to Arrowhead Pharmaceuticals?MorphoSys (NASDAQ:MOR) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends. Which has stronger valuation and earnings, MOR or ARWR? Arrowhead Pharmaceuticals has higher revenue and earnings than MorphoSys. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48N/AArrowhead Pharmaceuticals$829.45M12.73-$1.63M-$2.15N/A Do insiders & institutionals have more ownership in MOR or ARWR? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend MOR or ARWR? Arrowhead Pharmaceuticals has a consensus price target of $87.80, suggesting a potential upside of 17.14%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Arrowhead Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has more volatility and risk, MOR or ARWR? MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Does the media prefer MOR or ARWR? In the previous week, Arrowhead Pharmaceuticals had 7 more articles in the media than MorphoSys. MarketBeat recorded 7 mentions for Arrowhead Pharmaceuticals and 0 mentions for MorphoSys. Arrowhead Pharmaceuticals' average media sentiment score of 0.83 beat MorphoSys' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral Arrowhead Pharmaceuticals Positive Is MOR or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of -48.38% compared to MorphoSys' net margin of -226.79%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Arrowhead Pharmaceuticals -48.38%-55.09%-18.13% SummaryArrowhead Pharmaceuticals beats MorphoSys on 16 of the 17 factors compared between the two stocks.How does MorphoSys compare to Elanco Animal Health?MorphoSys (NASDAQ:MOR) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Do analysts prefer MOR or ELAN? Elanco Animal Health has a consensus price target of $28.20, indicating a potential upside of 29.55%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts plainly believe Elanco Animal Health is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Elanco Animal Health 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.77 Do institutionals & insiders believe in MOR or ELAN? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation and earnings, MOR or ELAN? MorphoSys has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48N/AElanco Animal Health$4.72B2.31-$232M-$0.50N/A Which has more volatility & risk, MOR or ELAN? MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Does the media prefer MOR or ELAN? In the previous week, Elanco Animal Health had 8 more articles in the media than MorphoSys. MarketBeat recorded 8 mentions for Elanco Animal Health and 0 mentions for MorphoSys. Elanco Animal Health's average media sentiment score of 0.67 beat MorphoSys' score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral Elanco Animal Health Positive Is MOR or ELAN more profitable? Elanco Animal Health has a net margin of -4.95% compared to MorphoSys' net margin of -226.79%. Elanco Animal Health's return on equity of 7.42% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Elanco Animal Health -4.95%7.42%3.66% SummaryElanco Animal Health beats MorphoSys on 14 of the 17 factors compared between the two stocks.How does MorphoSys compare to Dr. Reddy's Laboratories?Dr. Reddy's Laboratories (NYSE:RDY) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership. Do institutionals and insiders hold more shares of RDY or MOR? 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to RDY or MOR? In the previous week, Dr. Reddy's Laboratories' average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score. Company Overall Sentiment Dr. Reddy's Laboratories Neutral MorphoSys Neutral Which has more risk & volatility, RDY or MOR? Dr. Reddy's Laboratories has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Do analysts rate RDY or MOR? Dr. Reddy's Laboratories presently has a consensus target price of $16.90, suggesting a potential upside of 24.30%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, equities analysts clearly believe Dr. Reddy's Laboratories is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is RDY or MOR more profitable? Dr. Reddy's Laboratories has a net margin of 12.90% compared to MorphoSys' net margin of -226.79%. Dr. Reddy's Laboratories' return on equity of 12.16% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories12.90% 12.16% 8.12% MorphoSys -226.79%-694.31%-22.55% Which has stronger valuation & earnings, RDY or MOR? Dr. Reddy's Laboratories has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$3.58B3.17$484.20M$0.5823.44MorphoSys$238.28M11.99-$205.35M-$3.48N/A SummaryDr. Reddy's Laboratories beats MorphoSys on 11 of the 14 factors compared between the two stocks.How does MorphoSys compare to Abivax?MorphoSys (NASDAQ:MOR) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Does the media favor MOR or ABVX? In the previous week, Abivax had 7 more articles in the media than MorphoSys. MarketBeat recorded 7 mentions for Abivax and 0 mentions for MorphoSys. Abivax's average media sentiment score of 0.38 beat MorphoSys' score of 0.00 indicating that Abivax is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral Abivax Neutral Do insiders and institutionals believe in MOR or ABVX? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is MOR or ABVX more profitable? Abivax has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Abivax's return on equity of -146.43% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Abivax N/A -146.43%-88.69% Which has more volatility and risk, MOR or ABVX? MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Abivax has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Which has stronger valuation & earnings, MOR or ABVX? MorphoSys has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48N/AAbivaxN/AN/A-$380.27M-$5.21N/A Do analysts prefer MOR or ABVX? Abivax has a consensus price target of $137.15, indicating a potential upside of 12.43%. Given Abivax's stronger consensus rating and higher possible upside, analysts clearly believe Abivax is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Abivax 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.93 SummaryAbivax beats MorphoSys on 9 of the 16 factors compared between the two stocks.How does MorphoSys compare to Praxis Precision Medicines?Praxis Precision Medicines (NASDAQ:PRAX) and MorphoSys (NASDAQ:MOR) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability. Does the media favor PRAX or MOR? In the previous week, Praxis Precision Medicines had 3 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Praxis Precision Medicines and 0 mentions for MorphoSys. Praxis Precision Medicines' average media sentiment score of 0.04 beat MorphoSys' score of 0.00 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Overall Sentiment Praxis Precision Medicines Neutral MorphoSys Neutral Do analysts prefer PRAX or MOR? Praxis Precision Medicines currently has a consensus target price of $592.67, suggesting a potential upside of 72.51%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, research analysts plainly believe Praxis Precision Medicines is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Praxis Precision Medicines 2 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 4 Strong Buy rating(s) 2.95MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, PRAX or MOR? Praxis Precision Medicines has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Is PRAX or MOR more profitable? Praxis Precision Medicines has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Praxis Precision Medicines' return on equity of -43.02% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Praxis Precision MedicinesN/A -43.02% -40.22% MorphoSys -226.79%-694.31%-22.55% Do insiders and institutionals have more ownership in PRAX or MOR? 67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable earnings and valuation, PRAX or MOR? MorphoSys has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPraxis Precision Medicines$8.55M1,120.29-$303.27M-$13.37N/AMorphoSys$238.28M11.99-$205.35M-$3.48N/A SummaryPraxis Precision Medicines beats MorphoSys on 12 of the 17 factors compared between the two stocks. Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOR vs. The Competition ExportMetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86B$927.43M$6.45B$12.34BDividend YieldN/A4.84%2.76%5.28%P/E Ratio-5.451.4621.2225.65Price / Sales11.99119.63553.9286.28Price / CashN/A20.0743.4956.67Price / Book54.177.5910.377.14Net Income-$205.35M-$3.64M$3.57B$335.98M7 Day PerformanceN/A1.93%6.01%3.56%1 Month PerformanceN/A76.78%3.52%2.54%1 Year PerformanceN/A126.62%34.13%35.05% MorphoSys Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28MN/A730News CoverageARWRArrowhead Pharmaceuticals2.4955 of 5 stars$77.88-1.5%$87.80+12.7%+395.4%$10.97B$622.01MN/A400ELANElanco Animal Health4.6468 of 5 stars$21.84+1.9%$28.20+29.1%+71.9%$10.91B$4.72BN/A9,400Analyst DowngradeRDYDr. Reddy's Laboratories2.8995 of 5 stars$12.97+4.1%$16.90+30.4%-5.5%$10.82B$3.81B16.8427,811High Trading VolumeABVXAbivax2.9521 of 5 stars$121.91+0.4%$137.15+12.5%+2,051.5%$9.67BN/AN/A61Earnings ReportAnalyst UpgradeGap Up Related Companies and Tools Related Companies ARWR Competitors ELAN Competitors RDY Competitors ABVX Competitors PRAX Competitors CYTK Competitors KRYS Competitors IBRX Competitors NUVL Competitors PCVX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOR) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
